5th Jun 2014 11:22
LONDON (Alliance News) - Hutchinson China MediTech Ltd said Thursday that its majority owned research and development company has begun a Phase II clinical trial of drug fruquintinib for the treatment of non-small cell lung cancer in China.
The trial is targeted at patients who have failed second-line standard chemotherapy and will test the effectiveness and safety of the drug compared to a placebo.
The primary endpoint of the trial is progression free survival, with secondary endpoints being disease control rate, response rates, overall survival and safety. Progression free survival is the amount of time that a patient lives with a disease without it getting worse.
Around 90 patients will be enrolled and top-line results of the trial are expected in 2015.
The company entered into a licensing, co-development and commercialisation agreement for the drug with Eli Lilly and Co in China last October.
Shares in Hutchinson China MediTech were trading up 1.2% at 830.00 pence Thursday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed